Diagnostics
Veracyte Aims to Expand Diagnostics Reach With $50M NanoString Deal
7 days ago | By Xconomy
Veracyte, a company whose tests help physicians make treatment decisions, is adding technology from NanoString to the fold to expand its diagnostic capabilities. South San Francisco-based Veracyte announced Tuesday that it has reached a deal for global rights to develop and commercialize diagnostics based on the nCounter FLEX system. The nCounter is a NanoString instrument used to analyze the activity of genes. According to terms of the agreement, Veracyte will pay NanoString $40 million in cash, plus an additional $10 million in Veracyte stock. NanoString could receive an additional $10...
Read more ...
Search by Tags
Diagnostics Gene Genes National blog main New York blog main Raleigh-Durham blog main San Diego blog main San Francisco San Francisco blog main San Francisco top stories Seattle blog main Seattle top stories 10X Genomics Astellas Pharma Becton Dickinson Biotech Cancer Cancer diagnostics Deals Diagnostic Device Idiopathic pulmonary fibrosis Life Sciences Lung Cancer Lymphoma Medical Device Merck Nanostring VeraCyteWorld Biotechnology Congress 2019
Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...
World Biotechnology Congress 2019
Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...
2nd International Conference on Tissue Science and Regenerative Medicine
This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...
Perceptive Unveils New $200M Fund to Invest in Early-Stage Biotechs
Perceptive Advisors, an investment firm with a long track record of life science investing across all points of development, is now stepping up to pump money into companies at... Read more ...
Merck Makes a Big Blood Cancer Bet With $2.7B Deal for ArQule
Merck is acquiring cancer drug developer ArQule for $2.7 billion , a cash deal that brings it a promising early-stage compound that could challenge a blockbuster leukemia drug... Read more ...
KalVista Pharma Eye Drug Partnered With Merck Flunks Phase 2 Test
A KalVista Pharmaceuticals eye drug at the center of a research collaboration with Merck has failed a mid-stage clinical trial. KalVista developed its drug, KVD001, to treat... Read more ...
Zentalis Steps Out With $147M Raised to Develop “Tried and True” Small Molecules
Zentalis Pharmaceuticals is banking on small molecules for cancer-leaving the “cool technologies” aside for a “tried and true” approach, says the CEO, who wants to let the... Read more ...
Scripps Research, AbbVie Expand Drug Discovery Deal Beyond Cancer
The Scripps Research Institute and AbbVie have agreed to broaden an existing drug discovery agreement focused on cancer cell therapies to now encompass treatments for other... Read more ...
Eying Cancer Combos, Sanofi to Splash Out $2.5B on San Diego's Synthorx
Synthorx is working to design new cytokine therapies for cancer using an “extended” genetic alphabet that could help avoid the shortcomings associated with earlier versions... Read more ...
Artificial Pancreas Keeps Patients Healthier: A Perspective
The late Mayo endocrinologists Russell Wilder, M.D., and Randall Sprague, M.D., would be smiling today at the news for patients with diabetes. Much of their lives and careers... Read more ...
Aurinia Plans FDA Filing After Lupus Nephritis Drug Hits Phase 3 Goals
Aurinia shares spiked last week after voclosporin, an immunosuppressant being tested in patients with lupus nephritis, met its primary and secondary endpoints in a Phase 3... Read more ...
AstraZeneca Taps Gatehouse Bio to Identify Potential Drug Targets
After joining AstraZeneca's Boston Bio Hub incubator last year, Gatehouse Bio is now teaming up with the pharma company to identify potential drug targets in respiratory and... Read more ...
Business Development Manager, Europe - Invetech - San Diego, CA
Selling a combination of consulting services and technical product solutions in biotech, cell and gene therapy markets. Global VP Commercial .From Fortive - Tue, 10 Dec 2019... Read more ...